JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Other JAK2 inhibitors such as TG101209 and HBC were shown to have clinical efficacy against CML cell lines, and, in combination with imatinib, HBC significantly induced apoptosis in CML-BC cells.